> Hot share tips
> All the big AIM fraud exposés
> 300 articles and podcasts a month
> Original investigations by our experienced team
> No ads, no click-bait, no auto-play videos
By Tom Winnifrith | Thursday 1 January 2015
Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
One of the reasons that capitalism works while the alternative is doomed to fail is that failing companies can reinvent themselves.
For years AIM casino listed Vialogy misled investors raising money time and time again to support the obscene salaries of an underperforming and overpaid board. I like to think that I played a part in exposing the poltroons responsible and in forcing change. The old guard are out and shareholders are now starting to get back their losses as a new management team takes the ship, now renamed Premaitha (NIPT) forward.
This is now a biotech stock. I declare upfront that RMPC has a material holding. To get an idea of what the company – which still has c£5 million net cash – is up to watch its CEO present HERE
The company is working on commercialising a non-invasive test to see whether unborn babies have Down’s Syndrome – IONA. It is more accurate than existing tests and non-invasive so safer. Expect this company to get Kite mark approval within six weeks and that will be the precursor to the first sales agreements and thus a mammoth re-rating of the stock.
The value of the market Premaitha wishes to tap into is estimated at $4.2 billion. At a 19.5p offer the market cap is £36 million. Go figure as they say…
I expect Kite mark approval and the first commercial agreements to be driving this stock well past my 30p to sell initial target well before Easter and thus it is my sixth share tip of the year.
To read Tom Winnifrith’s first 2015 share tip of the year ( a buy) click HERE
To read Tom Winnifrith’s second 2015 share tip of the year ( a sell) click HERE
To read Tom Winnifrith’s third 2015 share tip of the year ( a sell) click HERE
To read Tom Winnifrith’s fourth 2015 share tip of the year ( a buy) click HERE
To read Tom Winnifrith's fifth 2015 share tip of the year ( a sell) click HERE
To read Tom Winnifrith’s 10 macro calls for 2015 click HERE
Never miss a story.
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Search ShareProphets |
Stock market news |
Recent Comments |